Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Nickel, MK; Nickel, C; Muehlbacher, M; Leiberich, PK; Kaplan, P; Lahmann, C; Tritt, K; Krawczyk, J; Kettler, C; Egger, C; Rother, WK; Loew, TH.
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.
J Clin Psychopharmacol. 2005; 25(3):211-217 Doi: 10.1097/01.jcp.0000162806.46453.38
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Nickel-Palczynski Marius
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The aim of this study was to compare the efficacy of topiramate versus a placebo in the treatment of adiposity in women undergoing olanzapine therapy. We also assessed changes health-related quality of life, the patient's actual state of health, and psychologic impairments. The 10-week, random, double-blind, placebo-controlled study included 43 women who had been treated with olanzapine (mean dose 7.8 +/- 3.6 in the topiramate group and 7.2 +/- 3.1 in the placebo group) and had gained weight as a side effect. The subjects were randomly assigned to topiramate (n = 25) or a placebo (n = 18). Primary outcome measures were weight checks and self-reported changes on the scales of the SF-36 Health Survey, Bf-S Scale of Well-Being, and the Adjective Checklist EWL-60-S. Weight loss was observed and was significantly more pronounced in the topiramate-treated group (difference in weight loss between the 2 groups: 5.6 kg, 95% CI = -8.5, -3.0, P < 0.001). In comparison with the placebo group, significant changes on 7 (7/8) scales of SF-36 Health Survey (all P < 0.001), on all 6 scales of the EWL-60-S, and on the Bf-S were observed in the topiramate-treated subjects after 10 weeks. All patients tolerated topiramate well. Topiramate appears to be a safe and effective agent in the treatment of weight gain that occurred during olanzapine treatment. Significantly positive changes in health-related quality of life, the patient's actual state of health, and psychologic impairments were observed.
Find related publications in this database (using NLM MeSH Indexing): Adipose Tissue - drug effects Adipose Tissue - metabolism; Adult -; Anti-Obesity Agents - therapeutic use; Benzodiazepines - adverse effects Benzodiazepines - pharmacology; Confidence Intervals -; Double-Blind Method -; Female -; Fructose - analogs and derivatives Fructose - pharmacology Fructose - therapeutic use; Humans -; Mental Disorders - drug therapy Mental Disorders - psychology; Neuropsychological Tests - statistics and numerical data; Statistics, Nonparametric -; Weight Gain - drug effects Weight Gain - physiology; Weight Loss - drug effects Weight Loss - physiology